/
Summary We are a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin , which we believe is a next-generation anthracycline and, with it, are conducting a pivotal Phase 3 trial in combination with cytarabine for the treatment of subjects with relapsed/refractory (R/R) acute myeloid leukemia (AML). W…
ROIC dropped from -127.15% to -181.76%, capital efficiency is deteriorating. Negative free cash flow of -$23M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$40M
▼ -28.8% YoY
Op. Margin
—
ROIC
-269.62%
▼ -54.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$24M
▲ +4.8% YoY
Op. Cash Flow (TTM)
-$24M
▲ +4.7% YoY
Net Debt
-$10M
Net Cash Position
Cash & Equiv.
$10M
Continue Research